Warfarin
Background
- Blocks activation of vit K thereby interfering w/ activation of factors II, VII, IX, X
- Also blocks synthesis of antithrombotic proteins C and S
- Causes transient (24-36hr) prothrombotic effect at the start of therapy
- Bridge with heparin until INR is in desired range for 2d
- Also blocks synthesis of antithrombotic proteins C and S
- Albumin bound; metabolized by liver
- Contraindicated in pregnancy
Dosing
- Day 1: 5-7.5 mg po QHS (to ensure absorption on an empty stomach)
- 2.5-7.5 mg thereafter (most often 5 mg)
- Increase in INR of >0.3-0.4 units per day necessitates dose reduction
- CHF, liver disease, Vitamin K def, drugs may influence warfarin response
Range (INR)
- 2.5-3.5: Mechanical prosthetic valves or recurrent thromboembolism
- 2.0-3.0: All other indications
Complications
- Bleeding
- Risk is increased when INR is in 3-4.5 range
- Exponential increase occurs when INR is >5
- Avoid giving pts NSAIDs, sulfas, macrolidies (azithromycin ok), fluoroquinolones
- Skin necrosis
- Primarily occurs in pts w/ protein C deficiency
- Occurs 3-8d after starting treatment
- Treatment
- Discontinue warfarin; start parenteral anticoagulant
- Vitamin K1 administration
Reversal
Source
Tintinalli
